Triggering of Inflammasome by Aggregated α-Synuclein, an Inflammatory Response in Synucleinopathies

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Codolo, Gaia ^a,b   Plotegher, Nicoletta ^a   Pozzobon, Tommaso ^b   Brucale, Marco ^c   Tessari, Isabella ^a   Bubacco, Luigi ^a   de Bernard, Marina ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CATHEPSIN B; CRYOPYRIN; FIBRILLAR ALPHA SYNUCLEIN; INFLAMMASOME; MONOMERIC ALPHA SYNUCLEIN; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOSOL; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENZYME RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; NEUROFILAMENT; PARKINSON DISEASE; PHAGOCYTOSIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SYNUCLEINOPATHY;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CARRIER PROTEINS; CHROMATOGRAPHY, REVERSE-PHASE; DNA PRIMERS; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; LEWY BODIES; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NEURONS; PARKINSON DISEASE; PHAGOCYTOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; THIAZOLES; TOLL-LIKE RECEPTOR 2;

EID: 84873123076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055375     Document Type: Article

References (66)

1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, et al. (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54: S21-23.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
3. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB, (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2: 14.
4. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473.
5. Gasser T, (2005) Genetics of Parkinson's disease. Curr Opin Neurol 18: 363-369.
6. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
7. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
8. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
9. Chiti F, Dobson CM, (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
10. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67.
11. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945-1947.
12. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20: 419-425.
13. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349: 162-166.
14. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113: 1435-1439.
15. Lee SJ, (2008) Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 34: 17-22.
16. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, et al. (2011) alpha-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci 5: 80.
17. Roodveldt C, Christodoulou J, Dobson CM, (2008) Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 12: 1820-1829.
18. Zhang W, Wang T, Pei Z, Miller DS, Wu X, et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19: 533-542.
19. Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, et al. (2008) Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3: 59-74.
20. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, et al. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185: 615-623.
21. Su E, Bell MJ, Wisniewski SR, Adelson PD, Janesko-Feldman KL,et al. alpha-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci 32: 385-395.
22. Su X, Federoff HJ, Maguire-Zeiss KA, (2009) Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 16: 238-254.
23. Theodore S, Cao S, McLean PJ, Standaert DG, (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67: 1149-1158.
24. Litteljohn D, Mangano E, Clarke M, Bobyn J, Moloney K, et al. (2010) Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis 2011: 713517.
25. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, et al. (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis 24: 183-193.
26. Beraud D, Maguire-Zeiss KA, (2012) Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. Parkinsonism Relat Disord 18 (Suppl 1):: S17-20.
27. Dinarello CA, (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40: 599-606.
28. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, et al. (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science 256: 97-100.
29. Keller M, Ruegg A, Werner S, Beer HD, (2008) Active caspase-1 is a regulator of unconventional protein secretion. Cell 132: 818-831.
30. Martinon F, Burns K, Tschopp J, (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10: 417-426.
31. Strowig T, Henao-Mejia J, Elinav E, Flavell R, (2012) Inflammasomes in health and disease. Nature 481: 278-286.
32. Schroder K, Tschopp J, (2010) The inflammasomes. Cell 140: 821-832.
33. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
34. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, et al. (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.
35. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J, (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
36. Hafner-Bratkovic I, Bencina M, Fitzgerald KA, Golenbock D, Jerala R (2012) NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1beta and neuronal toxicity. Cell Mol Life Sci.
37. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, et al. (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14: 1583-1589.
38. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
39. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J, (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140.
40. Cognet I, de Coignac AB, Magistrelli G, Jeannin P, Aubry JP, et al. (2003) Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods 272: 199-210.
41. Huang C, Ren G, Zhou H, Wang CC, (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 42: 173-177.
42. Ren G, Wang X, Hao S, Hu H, Wang CC, (2007) Translocation of alpha-synuclein expressed in Escherichia coli. J Bacteriol 189: 2777-2786.
43. van Gestel J, de Leeuw SW, (2006) A statistical-mechanical theory of fibril formation in dilute protein solutions. Biophys J 90: 3134-3145.
44. van Raaij ME, van Gestel J, Segers-Nolten IM, de Leeuw SW, Subramaniam V, (2008) Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory. Biophys J 95: 4871-4878.
45. LeVine H, 3rd (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404-410.
46. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
47. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.
48. Mankan AK, Kubarenko A, Hornung V, (2012) Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol 167: 369-381.
49. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, et al. (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11: 897-904.
50. Palokangas H, Metsikko K, Vaananen K, (1994) Active vacuolar H+ATPase is required for both endocytic and exocytic processes during viral infection of BHK-21 cells. J Biol Chem 269: 17577-17585.
51. Jin C, Flavell RA, (2010) Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol 30: 628-631.
52. Tassi S, Carta S, Delfino L, Caorsi R, Martini A, et al. (2010) Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci U S A 107: 9789-9794.
53. Beraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA,et al. Microglial Activation and Antioxidant Responses Induced by the Parkinson's Disease Protein alpha-Synuclein. J Neuroimmune Pharmacol.
54. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, et al. (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2: 253-258.
55. Maguire-Zeiss KA, Federoff HJ, (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. J Neural Transm 117: 1019-1025.
56. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ, (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69: 337-342.
57. McGeer PL, Itagaki S, Boyes BE, McGeer EG, (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
58. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, et al. (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21: 404-412.
59. Block ML, Zecca L, Hong JS, (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
60. Bisaglia M, Mammi S, Bubacco L, (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282: 15597-15605.
61. Djukic M, Mildner A, Schmidt H, Czesnik D, Bruck W, et al. (2006) Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 129: 2394-2403.
62. Getts DR, Terry RL, Getts MT, Muller M, Rana S, et al. (2008) Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med 205: 2319-2337.
63. Erridge C, (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
64. Comellas G, Lemkau LR, Nieuwkoop AJ, Kloepper KD, Ladror DT, et al. (2011) Structured regions of alpha-synuclein fibrils include the early-onset Parkinson's disease mutation sites. J Mol Biol 411: 881-895.
65. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, et al. (2010) Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5: e11765.
66. Li JY, Englund E, Holton JL, Soulet D, Hagell P, et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14: 501-503.